BRIEF—OMass Therapeutics raises £14 million in series A round

Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside Oxford Sciences Innovation (OSI).

The company, which is using structural mass spectrometry to discover novel medicines, says it will use the money to support pipeline development.

Chief executive Jonathan Hopper said: “OMass has pioneered the use of structural mass spectrometry for drug discovery, and this funding puts us in a position to take full advantage of that capability to identify novel drugs to precisely target large protein complexes.”